JAZZJazz Pharmaceuticals plc

$213.97+59% 1Y

$213.97

$131.1652 weeks$261.72

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap against its own history.

2 good, 1 without data

What the price assumes~−6% a yearderived · Jun 30, 2026

Priced for a decline (~−6% a year). The price demands less than its three-year revenue growth of 7% a year, expectations look modest.

Vs its own P/E rangecheaper than 90% of its own historyderived

Cheap vs its own history: P/E 14.6 vs a 20.1 median over 29 quarters (−27% vs median).

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Jazz Pharmaceuticals plc trades at 14.6× earnings against 19.8× for the median Biotechnology name, cheaper than its own group.

14.6

Trailing P/E · Biotechnology median 19.8 · cheaper than the typical name in its group

Price / sales: 3.63
Price / sales · as of 2026-Q2
Free cash flow yield: 11%
Free cash flow yield · Biotechnology median 4.3%
Growth the price implies: −5.5%
Growth the price implies · The price pays for −5.5% free cash flow growth a year for a decade; the business has delivered +5.5% a year over the last three.

Details›

What the market has paid for these earnings: 29 quarters of its own multiple × $14.63 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$247.79
Its own P/E history, median	$293.55
Its own P/E history, upper quartile	$356.54
52-week range	$131.16 – $261.72
Today	$213.97

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.